Renovion, Inc. is developing inhaled therapeutics designed to address both inflammation and infection in the airway. The Company's development efforts are based on a decade of research and discoveries at UNC-Chapel Hill. The company is currently in the pre-clinical stage and is unique in that the product has shown antibacterial, mucus transport and anti-inflammatory impact in patients. Renovion has completed a successful pre-IND meeting with the FDA and will plans to proceed rapidly through pre-IND and IND activities for lung transplant as our first indication. After this success we will expand to other therapeutic areas including cystic fibrosis, COPD and asthma. Further information regarding Renovion is available at www.renovion.com.